🧫 Experiment Protocol
Clinicaltype 2 diabetes, obesity, ischemic diseasehuman patientsproposed
This study evaluated the angiogenic capability of serum-derived extracellular vesicles (sEV) from different patient populations including type 2 diabetic subjects, obese individuals with and without diabetes, and subjects with ischemic disease. The research aimed to identify patients who may benefit from autologous sEV administration for pro-angiogenic therapy by comparing sEV properties across these different cardiovascular risk groups. The study involved both in-vitro and in-vivo assessment of angiogenic properties.
PRIMARY OUTCOME
sEV angiogenic capability
EXPECTED OUTCOMES
Different angiogenic properties between patient groups, identification of predictive biomarkers
SUCCESS CRITERIA
Differential angiogenic capability between patient groups
PROTOCOL
sEV isolation from serum, in-vitro and in-vivo angiogenic assays across patient groups